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This review focusses on gene discovery strategies used to identify monogenic forms of diabetes 
caused by reduced pancreatic beta cell number (due to destruction or defective development) or 
impaired beta cell function. Gene discovery efforts in monogenic diabetes have identifi ed 36 genes 
so far. These genetic causes have been identified using four main approaches: linkage analysis, 
candidate gene sequencing and most recently, exome and genome sequencing.  
The advent of next-generation sequencing has allowed researchers to move away from linkage 
analysis (relying on large pedigrees and/or multiple families with the same genetic condition) and 
candidate gene (relying on previous knowledge on the gene’s role) strategies to use a gene agnostic 
approach, utilising genetic evidence (such as variant frequency, predicted variant effect on protein 
function, and predicted mode of inheritance) to identify the causative mutation. This approach led 
to the identification of 7 novel genetic causes of monogenic diabetes, 6 by exome sequencing and  
one by genome sequencing. In many of these cases, the disease-causing gene was not known to be 
important for beta cell function prior of the gene discovery study.  
These novel findings highlight a new role for gene discovery studies in furthering our understanding 
of beta cell function and dysfunction in diabetes. Whilst many gene discovery studies in the past 
were led by knowledge in the field (through the candidate gene strategy) now they often lead the 
scientific advances in the field by identifying new important biological players to be further 














1. Introduction to monogenic diabetes 
Monogenic diabetes is caused by single gene mutations which most commonly results in beta cell 
dysfunction or destruction. There are two main subtypes, maturity-onset diabetes of the young 
(MODY) and neonatal diabetes. MODY is diagnosed during childhood or adulthood (>60% of cases 
diagnosed before 25 years) and accounts for ~3% of all cases of diabetes diagnosed under 30 years 
[1]. Neonatal diabetes is a much rarer condition (incidence ~1 case per 100,000 live births in 
European countries [2, 3]) and is diagnosed in the first 6 months of life. Monogenic forms of diabetes 
can also be one of the features of genetic syndromes involving multiple organs/tissues, for example 
maternally inherited diabetes and deafness (MIDD) caused by a mutation in the mitochondrial 
genome.  
Targeted treatment for monogenic diabetes is one of the first examples of precision medicine where 
the genetic subtype determines the patient’s treatment. Patients with MODY caused by mutations in 
the transcription factor genes HNF1A and HNF4A are sensitive to low dose sulphonylureas [4, 5]  and 
those with GCK mutations usually do not require any pharmacological treatment. Most patients with 
neonatal diabetes caused by mutations in the genes encoding the K-ATP channel subunits Kir6.2 or 
SUR1 (KCNJ11 or ABCC8) can be treated with high dose sulphonylureas [5, 6]. Stopping insulin 
improves quality of life [7], results in improved glycaemic control, reduces the risk of diabetic 
complications in later life and reduces healthcare costs [8]. Furthermore, improvements in cognitive 
function, motor skills and behaviour have been reported in patients with KCNJ11/ABCC8 mutations 
causing neonatal diabetes with developmental delay [9-11]. 
The identification of monogenic forms of diabetes has highlighted how important obtaining a genetic 
diagnosis is for a patient’s management. The clinical manifestations can be very similar between 
patients with different genetic subtypes, but the treatment and management options are often very 
different. The genetic diagnosis is therefore guiding patients’ clinical management as it can result in 
improved treatment, defines the prognosis and the recurrence risk  [12].  This is reflected in the 
current ISPAD guidelines for neonatal diabetes which advise immediate referral for genetic testing in 
patients diagnosed under the age of 6 months [12]. This has recently been reported to have resulted 
in neonatal diabetes patients now being referred for genetic testing less than 2 months after 
diagnosis with diabetes [13]. 
 
2. Gene discovery approaches in monogenic diabetes 
In addition to having important implications for patients’ clinical management, the identification of 
genes which, when disrupted, result in beta cell loss or dysfunction is very important for the 
diabetes research field as it can give fundamental insights into the pathogene sis of more common 
diabetes subtypes, such as type 1 and type 2. Furthermore, the identification of genes needed for 
beta cell formation during human embryonic development can provide important insights into the 
mechanisms regulating differentiation of stem cells into beta-cells. This knowledge could be crucial 
for current efforts aimed at generating functional beta cells from stem cells in vitro. Successful 
generation of beta cells in vitro is critical to overcome some of the main limitations currently being 
faced by islet transplantation approaches in patients with diabetes [13].      
Before the introduction of next generation sequencing to monogenic disease research in 2010, DNA 
sequencing allowed only analysis of short fragments of DNA covering one portion of ~500bp of a 
gene at the time. The most widely used sequencing technique was the Sanger method developed in 
the 1970s. This approach was labour intensive and time consuming, allowing for only a limited 
number of genes to be sequenced in any given individual. This meant that gene discovery studies 
had to use effective prioritising strategies to select the genes to sequence.  Traditionally, the most 
widely used (and successful) strategies for gene prioritisation have been the “candidate gene” and 
linkage analysis approaches. These approaches have resulted in the identification of the most 
common causes of neonatal diabetes (KCNJ11 [14], ABCC8 [15, 16], and INS [17, 18]) and MODY 
(HNF1A [19], HNF4A [20], and GCK [21]) and are further discussed in the following sections.  
In the last decade the introduction of next-generation sequencing technologies has enabled 
researchers to perform DNA sequencing at several orders of magnitude greater throughput than was 
previously possible. This has resulted in a big change in the approaches needed for successful gene 
discovery. The possibility of sequencing all the genes in the human genome in a single experiment 
has shifted the main challenge from selecting the right gene to sequence to selecting the right 
variants to follow up.  
Monogenic diabetes is clinically and genetically heterogeneous, with mutations in at least 36 genes 
reported so far (Table 1 and Figure 1). Discovery of these disease genes has resulted from linkage 
analysis, candidate gene sequencing and most recently, exome and genome sequencing. A list of 
monogenic diabetes genes, which strategy was used to identify them and a summary of the 
associated phenotypes are listed in Table 1. This review discusses the main gene discovery strategies 
and their most recent applications to identify genetic causes of monogenic diabetes, highlighting 
recent successes and challenges that remain to be addressed.  
 3. Monogenic diabetes found by linkage analysis 
Investigation of large pedigrees with multiple affected family members has historically been a 
valuable approach to identify disease-causing genes. Traditionally this included the investigation of 
highly polymorphic microsatellite markers in affected and unaffected individuals to identify a genetic 
region in which all affected individuals shared the same allele(s). The bigger the pedigree, the more 
refined the region would be, allowing the investigators to select only a small number of genes to 
further investigate to identify the causative variant. In cases in which large pedigrees with multiple 
affected members were not available, this approach could also be used to investigate multiple small 
families thought to have the same genetic condition in order to identify a shared genomic region 
among the areas of linkage identified in the different families. This approach has been successfully 
used in the past to identify mutations in 18 genes causing monogenic forms of diabetes, including 
mutations in two pancreatic transcription factor genes causing pancreatic agenesis (PDX1 [22] and 
PTF1A [23]), and more recently, to identify recessive mutations in the TRMT10A gene as a cause of 
young onset diabetes and primary microcephaly [24]. 
The main limitation to this approach is the requirement of large pedigrees and/or multiple pedigrees 
affected by the same genetic condition in order to be successful. This is often challenging when 
investigating a rare disease (like neonatal diabetes) or a disease with variable penetrance, such as 
MODY. Furthermore, whilst very useful for studying inherited conditions, a linkage analysis approach 
would not be effective when investigating a genetic condition caused by de novo mutations. 
However, linkage analysis remains a very powerful tool for gene discovery and it is still widely used 
in combination with next generation sequencing approaches to prioritise variants to follow up.  
 
3.1 Recent identification of a novel syndromic form of monogenic diabetes through linkage 
analysis 
The identification of the genetic aetiology of syndromic forms of monogenic diabetes is important to 
identify genes needed for the function of beta cells and other cell types. In 2013 Igoillo-Esteve et al 
reported the use of a combination of homozygosity mapping (a technique which identifies large 
stretches of homozygosity in the human genome) and linkage analysis to identify a homozygous 
nonsense mutation in the TRMT10A gene in two siblings born to related parents who had 
microcephaly and diabetes diagnosed in adolescence [24]. The authors went on to show that 
TRMT10A expression was high in both the adult and embryonic brain and in pancreatic islets.  
The role of TRMT10A in glucose control was confirmed by the identification of a homozygous 
missense variant in three patients with microcephaly who presented with hyperinsulinaemic 
hypoglycaemia which progressed to diabetes in adolescence [25]. 
Prior to this report TRMT10A was not suspected to be important for beta cells and it is still unclear 
how absence of this gene results in beta cell dysfunction. Igoillo-Esteve and colleagues proposed a 
mechanism through which TRMT10A expression in beta cells is regulated by endoplasmic reticulum 
stress and absence of functional TRMT10A would therefore result in beta cell and neuron apoptosis 
[24]. 
 
4. Monogenic diabetes found by a gene candidate approach 
The candidate gene strategy relies on the selection of a small group of genes which are suspected to 
be important for beta cell function and/or development based on previous studies conducted either 
in vitro or in vivo in animal models (most commonly mouse, frog, and zebrafish). This approach is 
based on the hypothesis that the mechanisms regulating beta cell function and development are 
conserved across species and therefore, if a gene is needed for beta cell development in mice, it is 
very likely to be needed for human beta cell development as well.  
One of the biggest successes for this approach in monogenic diabetes has been the identification of 
activating pathogenic variants in the KCNJ11 [14] and ABCC8 [15, 16] genes as the most common 
cause of neonatal diabetes in non-consanguineous populations. This finding consequently led to 
improved treatment in these patients who can be effectively treated with sulphonylurea tablets 
rather than insulin injections. 
Fifteen further monogenic diabetes genes have been identified using this strategy (Table 1), 
including most recently mutations in pancreatic transcription factors causing neonatal diabetes and 
adult onset diabetes as discussed below. This approach has therefore been very successful in the 
past, allowing the identification of some of the most common causes of monogenic diabetes. 
However as gene discovery efforts move towards rarer forms of the disease, using this strategy has 
become more challenging, mainly because of two limitations: 1) reliance on current knowledge and 
2) prior assumption that the genes important for beta cell function in animal models are also 
fundamental for human beta cells.  
 
4.1 Recent application of a candidate gene approach to find two novel genetic causes of neonatal 
diabetes resulting in defective beta cell development 
The number of potential candidate genes for beta cell dysfunction is constantly increasing as more 
studies (including animal model phenotyping, genome wide association studies for type 1 and type 2 
diabetes, and in vitro studies looking at expression and regulation of beta cells during 
differentiation) are published. For example, the International Mouse Phenotypic Consortium 
database [26] lists 534 genes associated with abnormal glucose homeostasis in mouse models. 
Prioritisation strategies are therefore needed to decide which genes to follow up. One recent 
example of how to refine the candidate gene approach has been reported by Flanagan and 
colleagues [27] who combined mapping of the homozygous regions with a candidate gene approach. 
In this study 29 transcription factor genes known to be important for pancreatic development in 
mice were systematically investigated in 147 patients with neonatal diabetes born to related 
parents. The authors hypothesised that these patients were likely to have a homozygous mutation 
causing their diabetes and used homozygosity mapping to investigate whether any of the 29 
candidate pancreatic developmental factor genes were included in one of the large homozygous 
regions identified in the patients. This approach identified two patients with homozygous loss of 
function mutations in the NKX2-2 gene and 2 patients with homozygous missense variants in MNX1.  
The patients’ clinical features were found to be very similar to the phenotypic characteristics 
described in mouse models in which the genes had been knocked out. The two patients with NKX2-2 
homozygous mutations had permanent neonatal diabetes and small corpus callosum. Consistent 
with this, the Nkx2-2 knock-out mouse model was reported to develop diabetes soon after birth and 
to have reduced beta cell number and abnormal islet morphology [28]. The Nkx2-2 knock-out mice 
also have neurological features including delayed oligodendrocyte differentiation and absence of 
hindbrain serotonergic neurons [29, 30]. 
The two patients with homozygous MNX1 mutations reported by Flanagan et al had neonatal 
diabetes and severe intrauterine growth retardation. Only one of the two patients had additional 
extra-pancreatic features, whilst the other patient had neonatal diabetes and failure to thrive. This is 
clinically very different from the clinical features usually described in patients with Currarino 
syndrome which is caused by dominant loss of function MNX1 mutations [31]. The Mnx1 knock-out 
mouse model has intrauterine growth retardation and abnormal pancreatic development, with 
decreased beta cell number and abnormal islet morphology [32]. This is again very similar to the 
pancreatic phenotype observed in the two patients with neonatal diabetes. 
This study had shown how successful a candidate gene approach can still be in the post next 
generation sequencing era, provided that the analysis of candidate genes is integrated with other 
prioritisation strategies, such as homozygosity mapping. 
 
4.2 A candidate gene approach to identify RFX6 dominant mutations as a cause of MODY 
Mutations in the HNF1A, HNF4A and GCK genes are the most common genetic causes of isolated 
adult onset diabetes accounting for ~35% of patients with a MODY phenotype [1]. Identifying the 
genes that can cause isolated adult onset diabetes can give important insights into the pathogenesis 
of type 2 diabetes, by identifying factors and pathways needed for beta cell function. In order to try 
and identify novel genetic causes of MODY, Patel et al [33] used a next generation sequencing assay 
to analyse 29 genes known to cause neonatal diabetes, MODY and mitochondrial diabetes, 
lipodystrophy or other forms of syndromic diabetes in parallel in 38 patients who, based on their 
clinical features, were considered to be very likely to have a mutation in a single gene causing their 
diabetes. Using this approach the investigators identified two patients heterozygous for a nonsense 
RFX6 variant. The frequency of heterozygous protein-truncating variants was then assessed in a 
larger cohort of 348 patients referred for MODY genetic testing and found to be significantly higher 
than in population datasets. This study led to the identification of RFX6 mutations as the cause of 
MODY in 27 patients diagnosed at a median age of 32 years. Interestingly, the authors found that 
the penetrance of the RFX6 heterozygous mutations was lower than for other MODY subtypes 
(namely HNF1A and HNF4A), and suggested that this is likely to be one of the reasons why gene 
discovery in adult onset diabetes is often very challenging. 
RFX6 is crucially important for development of the human beta cells and biallelic mutations cause a 
syndromic form of neonatal diabetes which includes pancreatic hypoplasia/annular pancreas, 
gallbladder agenesis and intestinal atresia [34]. The results reported by Patel et al highlight RFX6’s 
important role in adult beta cell physiology as well as development. This study also shows the value 
of candidate gene studies in large patient cohorts, allowing for replication of the initial genetic 
finding and overcoming the challenges presented by studying a heterogeneous disease with reduced 
penetrance. 
 
5. Monogenic diabetes found by next generation sequencing - exome sequencing with a gene 
agnostic approach 
The term next-generation sequencing collectively refers to the high throughput DNA sequencing 
technologies which are able to sequence a large amount of DNA sequences in a single experiment. 
The introduction of next-generation sequencing technologies to the market in 2005 and their 
subsequent improvement has resulted in the ability to sequence entire exomes and genomes quickly 
and at an affordable price for routine research and diagnostic tests. Next-generation sequencing 
approaches are now extensively used both for new disease genes discovery and for improving 
diagnostic genetic tests for known diseases. 
The most widely used applications of next-generation sequencing are targeted sequencing of a panel 
of genes followed by exome sequencing with genome sequencing becoming more popular as prices 
fall. Exome sequencing allows simultaneous analysis of the ~2% of the human genome which 
encodes for proteins. About 80% of disease-causing mutations are predicted to be located in a 
protein-coding part of the genome (although this may be due to ascertainment bias as most studies 
only analyse the coding regions) [35], thus making exome sequencing an attractive strategy to 
investigate the genetic basis of monogenic diseases.  
Typically, between 20,000 and 50,000 variants are identified per exome [36]. Filtering and 
prioritizing strategies are needed to reduce this number to a small subset of variants that are most 
likely to be pathogenic. The filtering steps applied to exome sequencing data account for qualitative 
requirements, predicted effect of the variant on the protein and whether the variant is known to be 
common in the general population (as reported in GnomAD [37] and internal databases when 
available). Generally, these steps leave 150–500 variants to be further assessed as potentially 
pathogenic [38]. This number is generally too large to allow follow-up of all the variants, and 
additional prioritisation strategies are needed. These strategies are generally based on the likely 
inheritance pattern of the disease (e.g. looking for recessive mutations in a linkage interval or de 
novo mutations in apparently sporadic disease). This strategy is often referred to as the ‘gene 
agnostic’ approach, as the filtering strategies used to prioritise the variants don’t necessarily rely on 
prior knowledge of a gene’s role, but on the predicted effect of the variant and the inheritance 
pattern. 
More than 200 genes causing Mendelian disorders have been identified using exome sequencing, 
including six novel causes of monogenic diabetes [38-43]. 
 
5.1 Identification of new genetic causes of pancreatic agenesis by exome sequencing  
Neonatal diabetes due to pancreatic agenesis is characterized by insulin dependent diabetes and 
pancreatic exocrine insufficiency requiring enzyme supplementation therapy [38]. This is an 
extremely rare condition which is most likely caused by a mutation in a single gene needed for 
pancreatic development. Identifying the genes that regulate pancreatic development in humans can 
give important insights into the factors needed to make functional beta cells and has the potential to 
be translated into optimisation of in vitro protocols to differentiate stem cells into beta cells. 
Until 2012, only recessive mutations in two pancreatic developmental factors, PDX1 and PTF1A, had 
been identified to cause pancreatic agenesis in humans through a combination of linkage and 
candidate gene studies. Mutations in PDX1 had been described in 4 cases with isolated agenesis of 
the pancreas [22, 44, 45]. Mutations in PTF1A had been reported in 4 families in which affected 
individuals had both pancreatic and cerebellar agenesis [23, 46, 47].  
In 2012 Lango Allen and colleagues investigated 27 patients diagnosed with pancreatic agenesis [38] 
and reported that most patients with syndromic pancreatic agenesis were born to unaffected 
unrelated parents. This suggested that the mutation causing syndromic pancreatic agenesis was 
most likely sporadic. To investigate this hypothesis the authors performed exome sequencing of two 
unrelated patients with pancreatic agenesis and congenital heart defects and their unaffected, 
unrelated parents with the aim of investigating variants present in the affected patient but not 
inherited from either parent. After exclusion of common variants, only one de novo variant was 
confirmed in each patient. Both variants, a missense and a frameshift deletion, affected the coding 
region of the developmental factor gene GATA6. Lango Allen and colleagues then sequenced GATA6 
in 25 additional patients with pancreatic agenesis and identified mutations in 13 additional cases  
[38]. The authors concluded that heterozygous mutations in GATA6 are a common cause of 
pancreatic agenesis.  
GATA6 is a transcription factor involved in early embryonic development of multiple organs, 
including the pancreas [48]. Interestingly, previous studies on mouse models were not suggestive of 
a role of Gata6 in pancreatic development in rodents [48, 49] and therefore investigation of GATA6 
in patients with neonatal diabetes had not been considered before. In this case exome sequencing 
led to the identification of a novel disease gene and gave unexpected insights into human pancreatic 
development. 
The identification of mutations in GATA6 as a major cause of syndromic pancreatic agenesis in 
humans highlighted the potential of the gene agnostic approach, demonstrating the existence of 
fundamental differences in the genes regulating pancreatic development in mouse and human, an 
important limitation of the ‘candidate-gene’ approach.  
The difference between development of the pancreas in mice and human was further highlighted by 
the recent report of a specific CNOT1 mutation, p.(Arg535Cys), as causing a novel syndrome of 
pancreatic agenesis and holoprosencephaly [40]. In this study, De Franco and colleagues performed 
exome sequencing for 9 patients with pancreatic agenesis and their unaffected, unrelated parents 
(available in 7 cases). The same novel, heterozygous CNOT1 missense mutation was found in 3 
patients and confirmed to have arisen de novo in 2 of them (the maternal sample was not available 
for the third patient). Two of the patients were diagnosed with pancreatic agenesis and partial 
holoprosencephaly (a neurodevelopmental condition resulting from failure of the brain to separate 
into two hemispheres). The third patient had pancreatic agenesis and dysmorphic facial features 
suggestive of possible holoprosencephaly, but this could not be confirmed as MRI was declin ed by 
the parents. The identification of the same de novo variant in 3 patients with a very similar 
phenotype, led the authors to hypothesise that a mutation-specific mechanism rather than 
haploinsufficiency was responsible for the phenotype.  
To test this hypothesis, the authors used CRISPR/Cas9 genome editing to generate a mouse model 
harbouring the Cnot1 p.(Arg535Cys) variant. Interestingly, mice heterozygotes for the Cnot1 
mutation, which theoretically should have mirrored the human disease, had normal glucose 
tolerance and no gross abnormalities. However, homozygosity for the mutation was embryonically 
lethal and analysis of the embryos at e14.5 showed a range of brain defects and a markedly small 
dorsal pancreas compared to wild type and heterozygotes littermates [40]. 
A second study investigating the genetic causes of holoprosencephaly reported detection of the 
CNOT1 p.(Arg535Cys) mutation in a patient with holoprosencephaly and neonatal diabetes (the 
second patient reported did not have diabetes), confirming the role of this mutation in pancreatic 
and brain development [50].  
CNOT1 is a repressor of transcription known to act both as an independent factor and as the scaffold 
protein of the CCR4-NOT complex [51]. Before the recent identification of the p.(Arg535Cys) 
mutation in patients with syndromic pancreatic agenesis, i t had never been thought to have a 
specific role in brain and pancreatic development. In vitro studies had however suggested that 
CNOT1 is needed for maintaining human and mouse embryonic stem cell pluripotency through 
inhibition of early endodermal differentiating factors [52], including the known pancreatic 
developmental transcription factors GATA4 and GATA6. De Franco and colleagues have therefore 
proposed a possible mechanism through which the p.(Arg535Cys) mutation causes pancreatic 
agenesis [40]. They suggested that the mutation could result in CNOT1 maintaining its inhibition on 
the GATA factors which in turn would result in continued expression of the SHH factor (which needs 
to be switched off for pancreatic development) and affected pancreatic development.  
This finding highlights a possible new mechanism disrupting pancreatic development by affecting the 
very early stages of embryonic stem cell differentiation and reiterates the importance of gene -
agnostic approaches to gain new biological insights into human pancreatic development.  
 
5.2 Identification of new genetic causes of monogenic autoimmunity by exome sequencing 
In some cases diabetes diagnosed before 6 months can be caused by mutations in a single gene 
causing severe early-onset autoimmunity leading to beta cell destruction. The most common of 
these conditions is IPEX syndrome (Immune dysregulation, Polyendocrinopathy, Enteropathy, X -
linked), caused by mutations in the FOXP3 gene [53]. Identification of the genes causing these 
conditions can give important insights into the mechanisms involved in the pathogenesis of more 
common autoimmune diseases, such as type 1 diabetes.  
In order to identify novel genes causing early-onset syndromic autoimmune disease, Flanagan and 
colleagues [41] performed exome sequencing of a proband/parents trio for a patient diagnosed with 
diabetes at 2 weeks and additional early-onset autoimmune features (autoimmune hypothyroidism 
diagnosed at 3 years and celiac disease diagnosed at 17 months). A single de novo mutation in the 
transcription factor gene STAT3 was identified. Sequencing of STAT3 in 63 additional patients 
identified 3 mutations in 4 individuals.  
Functional studies on the mutated STAT3 protein showed that the variants identified in patients with 
the early-onset polyautoimmunity phenotype were all activating mutations, whilst inactivating 
STAT3 mutations had been previously reported to cause the immunodeficiency disease, Hyper IgE 
syndrome [54]. The authors propose a mechanism in which STAT3 activating mutations lead to early 
autoimmunity by impairing the development of regulatory T cells [41]. 
The identification of STAT3 mutations in patients with syndromic monogenic autoimmune disease 
has opened the possibility of personalised therapies to treat at least some of the most debilitating 
features of the condition in these patients. One example was reported by Milner et al [55] who 
showed significant improvement of the polyarthritis and skin tightening in a patient with a STAT3 
activating mutation when they were treated with an anti-IL6R monoclonal antibody. 
Another genetic cause of monogenic autoimmunity including diabetes was recently reported by  
Johnson et al [42]. This study described the use of exome sequencing in a patient with neonatal 
diabetes and additional autoimmune features to identify compound heterozygous loss of function 
mutations in the LRBA gene. The authors conducted replications studies in 169 patients diagnosed 
with diabetes before the age of 12 months to identify a further 9 patients from 8 families with 
biallelic LRBA mutations and early onset diabetes (with age at diagnosis ranging from 6 weeks to 15 
months). Most patients had additional autoimmune features, including haematological disorders, 
enteropathy, hypothyroidism and recurrent infections. Interestingly, one patient had isolated 
permanent neonatal diabetes when last assessed at the age of 2 years, suggesting that diabetes can 
be the presenting feature of this phenotypically heterogeneous disorder.  
Biallelic mutations in LRBA had been previously identified in 2012 to cause common variable 
immunodeficiency with autoimmunity [56] however diabetes was considered to be a rare feature of 
the disease and, when present, was diagnosed outside the neonatal period. Johnson et al have 
reported that LRBA mutations were picked up in a high proportion of patients born to related 
parents and diagnosed with diabetes between 6 and 12 months of age, recommending inclusion of 
this gene in current genetic testing strategies for neonatal and early onset diabetes  [42]. 
Early detection of an LRBA mutation in patients is crucially important as it can guide treatment 
decisions. When Loper-Herrera et al first reported the identification of mutations in LRBA as a cause 
of common variable immunodeficiency with autoimmunity using linkage analysis the gene function 
was completely unknown. Following this discovery, Lo et al hypothesised that LRBA could be 
controlling the expression of one of the master-regulators of immunity, CTLA4 [57]. This was 
confirmed by the marked clinical improvement of most symptoms in 9 patients with recessive LRBA 
mutations who were treated with Abatacept, a fusion drug replacing CTLA4 already used for 
treatment of rheumatoid arthritis. This is an important example of how the identification of 
mutations in LRBA as a cause of monogenic autoimmunity led to defining the role of the gene and 
developing a targeted therapy for the patients with this rare monogenic condition.   
In the cases discussed in this section the identification of two novel causes of early onset diabetes 
using exome sequencing gave important insights into the complex mechanisms leading to 
autoimmunity and has contributed to development of better therapeutic options for patients . 
 
5.3 Identification of a syndromic form of adult onset diabetes by exome sequencing 
Exome sequencing can be extremely successful in identifying the genetic aetiology for clinically well-
defined entities for which the previous approaches had failed. This was indeed the approach used by 
Cordeddu et al to identify the genetic cause of Primrose syndrome [58], a neurodevelopmental 
disorder often associated with a microdeletion of 5 genes at the 3q13 region. Exome analysis of 4 
affected individual and their unrelated, unaffected parents identified de novo heterozygous 
mutations in the zinc finger transcription factors ZBTB20 in all four patients. Replication studies 
identified heterozygous ZBTB20 mutations in 4 further individuals with a suspected diagnosis of 
Primrose syndrome. When clinically assessed, it was found that 4/7 patients with ZBTB20 de novo 
mutations had diabetes and 3/7 had abnormal glucose tolerance (data was not available on the 8th 
individual).  
Although the mechanism through which ZBTB20 mutations cause diabetes in patients with Primrose 
syndrome is unclear, mouse studies had previously shown that Zbtb20 is highly expressed in beta 
cells. The function of this transcription factor in the mouse beta cell was further confirmed by the 
characterisation of a beta cell-specific Zbtb20 knock out mouse model which was found to develop 
hyperglycaemia through severely impaired glucose-stimulated insulin secretion [59].  
The identification of heterozygous de novo ZBTB20 mutations in patients with Primrose syndrome 
and diabetes confirms that this gene is fundamentally important for human as well as mice beta 
cells, highlighting a pathway which could be relevant to the pathogenesis of type 2 diabetes. 
 
5.4 Identification of a novel WFS1-related disease by exome sequencing 
Biallelic mutations in WFS1 cause Wolfram syndrome [60], a degenerative condition characterised by 
early-onset diabetes (median age at onset 6 years, range 1–32 years [39]), which is often the 
presenting feature, followed by the development of optic atrophy, diabetes insipidus and deafness. 
Heterozygous dominantly-acting WFS1 variants have been reported to cause ‘milder’ or ‘incomplete’ 
forms of Wolfram syndrome, including isolated deafness [61, 62], isolated nuclear cataracts [63], 
deafness and optic atrophy [64-66]. In 2013 Bonnycastle et al used a combination of exome 
sequencing and linkage analysis to identify the genetic cause of diabetes (diagnosed between 18 and 
51 years of age) in a multigenerational Finnish family [67]. They identified a novel WFS1 
heterozygous variant, p.(Trp314Arg), which co-segregated with diabetes in the family. In vitro 
functional studies showed that this variant was likely to impair the WFS1 protein’s ability to suppress 
endoplasmic reticulum stress after its induction. 
More recently, De Franco and colleagues reported the identification of a de novo heterozygous 
WFS1 variant, p.(Glu809Lys), in a patient with neonatal diabetes, congenital cataracts, sensorineural 
deafness, hypotonia, and dysmorphic features [39]. Replication studies identified de novo 
heterozygous missense variants in WFS1 in 4 further patients, including 2 additional patients 
harbouring the same WFS1 p.(Glu809Lys) mutation as the index patient. The clinical features were 
remarkably similar among the 5 patients, with all of them having low birth weight, early onset 
diabetes (diagnosed between 13 and 50 weeks of age) and deafness. Four of the five patients also 
had congenital cataracts and hypotonia. The authors noted that the phenotype in these 5 patients 
was very different from classical Wolfram syndrome, leading to the hypothesis that the mutations 
identified have a dominant negative effect. Functional in vitro studies confirmed this hypothesis, 
showing that the mutations resulted in a misfolded protein which causes severe endoplasmic 
reticulum stress as well as resulting in a WFS1 protein unable to suppress the endoplasmic reticulum 
stress response. 
This study expanded the clinical spectrum associated with mutations in WFS1, defining a novel 
syndromic form of neonatal diabetes. These findings give important insights on how the WFS1 
protein is fundamentally important for beta cell survival and highlight the potential of gene agnostic 
approaches in identifying new genetic mechanisms involving known disease genes.  
 
5.5 Identification of EIF2S3 mutations as causing an X-linked syndrome which can include early 
onset diabetes 
Exome sequencing of proband/parents trios is very effective to identify de novo and 
homozygous/compound heterozygous variants. It is however more challenging to identify 
pathogenic variants that cause disease through an X-linked recessive mode of inheritance where 
affected males often inherit the variant from unaffected (or mildly affected) mothers. 
Skopkova and colleagues successfully identified EIF2S3 variants as the cause of X-linked MEHMO 
syndrome (a complex disease including mental retardation, epileptic seizures, hypogonadism and 
hypogenitalism, microcephaly, obesity and, in some cases, early onset diabetes) by performing 
exome sequencing on 4 affected individuals with similar clinical features [43]. Since all the affected 
were males, the authors focussed their analysis on rare, predicted deleterious variants on the X 
chromosome. All four patients were found to be hemizygous for rare EIF2S3 variants. Functional 
studies on patients’ fibroblasts and in yeast cells confirmed that the mutations were severely 
affecting the function of the protein encoded by EIF2S3. 
EIF2S3 encodes for the translation initiation factor eIF2γ which is important for regulation of protein 
translation both under basal conditions and when there is endoplasmic reticulum stress. The results 
of this gene discovery study confirm the importance of this gene for many cell types, including beta 
cells. 
 
6. Genome sequencing 
The cost of genome sequencing has been steadily falling in recent years, leading many researchers to 
prefer this more comprehensive approach to exome sequencing. Genome sequencing allows the 
analysis of almost the entire genomic sequence (~98% [68]), without prior selection of specific 
regions. Each genome sequenced produces about 200 Gb of data with 3-4 million single nucleotide 
variants expected to be detected in each individual.  
Genome sequencing presents some important technical advantages compared to exome 
sequencing: it is more sensitive and accurate for detecting structural variation (such as insertions, 
deletions, and translocations), it allows more even coverage than exome sequencing allowing more 
accurate variant detection, and can identify variants in intronic and intergenic regions.  However, 
although genome sequencing is considered the most comprehensive strategy to d ate [69], the 
technology still presents some important limitations, mainly due to the use of short (~150-300 bp ) 
fragments sequencing. This is currently a necessary requirement to obtain high sequence quality , 
but it also means that complex genomic regions (for example regions with very high GC content or 
highly repetitive elements), are impossible to map and therefore to analyse. This can result in 
genetic diagnosis being missed. The advent of technologies allowing sequencing of long (usually >10 
kilobase) reads from single DNA molecules, such as the Oxford Nanopore [70] and PacBio [71] 
technologies, is a promising avenue to overcome these limitations. These technologies have been 
used successfully to investigate complex rearrangements and tandem repeats in know disease 
genes. However their routine use for human genome sequencing is currently hampered by the high 
error rate (~13%) and the high cost/throughput ratio, which is however constantly decreasing.   
6.1 Identification of PTF1A non-coding variants causing pancreatic agenesis using genome 
sequencing 
The main obstacles to the widespread use of (short read) genome sequencing for gene discovery 
have been the the enormous amount of data produced, resulting in challenging data analysis. Most 
of the studies reporting the use of genome sequencing so far have limited the initial variants analysis 
to the coding part of the genome and have proceeded to the investigation of the non -coding 
variants just when a causative variant could not be identified in the exome.  
So far, the most successful application of whole genome sequencing in monogenic diabetes has been 
the identification of mutations in a previously unrecognised regulatory element of the PTF1A gene 
[72] in patients with isolated pancreatic agenesis. 
Recessive mutations in the gene encoding for the transcription factor PTF1A are a known cause of 
pancreatic and cerebellar agenesis. In 2014 Weedon and colleagues reported the use of linkage and 
genome sequencing to identify the genetic cause of isolated pancreatic agenesis  in a cohort of 
patients born to related parents [72]. The authors studied 3 consanguineous pedigrees which 
included multiple affected individuals, suggesting a recessive pattern of inheritance. Linkage analysis 
in the 3 families highlighted a single shared locus on chromosome 10, including the PTF1A gene. 
However no coding mutation segregating with the disease was identified.  
Genome sequencing was subsequently performed in 2 patients. Initial analysis of the coding variants 
failed to identify the genetic cause. The authors then concentrated on variants affecting regulatory 
elements involved in early pancreatic development identified by epigenomic mapping in pancreatic 
progenitor cells. A single shared homozygous variant located in a highly conserved region ~25kb 
downstream of PTF1A was identified. Sequencing analysis of the ~500bp-long putative regulatory 
element in 19 additional probands with pancreatic agenesis identified a mutation in 8 individuals.  
Functional studies confirmed that the regulatory element was a previously unrecognised PTF1A 
enhancer which is active only during pancreatic development [72]. The authors suggested that this is 
likely to explain why patients with mutations in the PTF1A distal enhancer do not present with the 
severe cerebellar phenotype caused by the majority of PTF1A coding mutations [23, 46, 47].  
This study is an important example of the application of genome sequencing to identify pathogenic 
non-coding variants and uncovers the role of a previously unsuspected regulatory element needed 
for normal pancreatic development in humans.   
7. Challenges and opportunities 
Following the initial successes of candidate gene and linkage analysis approaches, the introduction 
of next generation sequencing technologies has resulted in the identification of 6 novel genetic 
causes of neonatal-early onset diabetes and 1 novel genetic cause of syndromic adult onset diabetes 
though beta cell dysfunction in the last 7 years.  
The identification of 6 novel genetic causes of neonatal diabetes has increased the proportion of 
patients in whom a genetic aetiology can be successfully identified to over 82% [12]. This proportion 
is even higher in patients with pancreatic agenesis for whom mutations in the known genes account 
for 97% of cases [40]. This is in sharp contrast with the success rate of gene discovery in MODY 
patients, for whom the pick-up rate is 35-45% [1]. One of the main challenges that explain why gene 
discovery has so far been less successful in MODY cohorts is patient selection for gene discovery 
studies. Whilst for neonatal diabetes the age at diagnosis cut-off of 6 months [2, 73] enriches patient 
cohorts for individuals who are likely to have a mutation in a single gene, it remains extremely 
challenging to distinguish the rare patients with adult onset monogenic diabetes from the much 
more common type 1 and type 2 diabetes using clinical features alone. A powerful tool that has the 
potential to overcome this obstacle is the use of genetic risk scores to identify patients who are 
genetically at high risk of developing type 1 [74-76] and type 2 diabetes [77, 78]. Pre-screening 
patients using genetic risk scores before gene discovery studies could greatly help researchers to 
select patients who are most likely to have a monogenic cause for their disease.  
Another important challenge for gene discovery studies is the rarity of some genetic conditions, 
making replication of the genetic finding in three unrelated families an extremely challenging and 
lengthy process. Some international platforms such as GeneMatcher [79] are addressing this issue by 
allowing scientist from all over the world to input a candidate gene of interest in their freely 
available web-app and putting them in contact with other centres who have also submitted an entry 
for the same gene. These efforts are aimed at making the genetic replication process for rare genetic 
diseases easier and more efficient by encouraging scientists to share their data and building new 
international collaborations.  
The vast majority of the gene discovery studies published so far have only analysed the ~2% of 
genomic sequence which is known to encode for proteins (the exome). As described above, this 
approach has been very successful in many cases, but there are still >10% of patients with neonatal 
diabetes and ~50% of patients with adult onset diabetes without a genetic diagnosis. Whilst some of 
these patients might have a very rare mutation in a novel gene which has not been replicated in a 
second family yet, it is likely that at least some of them have a mutation in the ~98% of the genome 
that was not initially investigated. Non-coding variants could affect splicing or be located in 
important regulatory regions (promoters or enhancers) which can be tissue and developmental 
stage-specific (as in the case of the PTF1A enhancer mutations in patients with pancreatic agenesis 
[72] discussed in the previous sections). The next challenge for gene discovery will be to develop 
strategies to prioritise, filter and interpret the large amount of non-coding variants identified by 
genome sequencing to identify disease-causing mutations. The identification of non-coding (in 
particular regulatory) mutations causing diabetes can shed important insights onto the genomic 
regions regulating beta cell function and potentially offer insights into the mechanisms of other 
types of diabetes such as type 1 and type 2. 
8. Perspective – a new role for gene discovery 
The recent successes in using gene agnostic approaches to identify genetic causes of monogenic 
diabetes have highlighted a new role for gene discovery in science. Before, when the candidate gene 
approach was the most commonly used strategy, the identification of a genetic mutation causing 
diabetes in humans was often confirmatory of the role of a candidate gene in human beta cells.  
Now, the use of a gene agnostic approach often results in the identification of disease-causing 
mutations in genes that either have no known function or had not been previously thought to be 
important for beta cells. This means that gene discovery is often becoming the starting point from 
which to perform further in vitro and in vivo studies to accurately define the role of the gene and the 
mechanism through which it is causing the disease. Gene discovery is therefore opening new 
avenues of research, highlighting novel biological mechanisms which are often specific to humans 
and would be very hard (and in some cases impossible) to identify using animal models. If gene 
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Table 1. Monogenic forms of diabetes. This table lists monogenic form of diabetes caused by 
defective pancreatic beta cell function, development or destruction that would be classified as 
diagnostic-grade according to the criteria used by PanelApp 
(https://panelapp.genomicsengland.co.uk/#!Guidelines) and ClinGen [80]. This is not a 
comprehensive list of syndromes which can include diabetes. In addition, methylation defects that 
result in the overexpression of the paternally inherited genes PLAGL1 and/or HYMAI genes are the 
most common cause of transient neonatal diabetes although the exact molecular mechanism is 
unknown [81] 
Gene Inheritance Phenotype Method of 
discovery 
Reference 





syndrome or MODY 
Candidate gene [15, 16, 82, 83] 




CISD2 Recessive Wolfram Syndrome 
2 
Linkage [85] 





Exome sequencing [40, 50] 
DCAF17 Recessive Woodhouse-Sakati 
syndrome 
Linkage [86, 87] 















[53, 91, 92] 
GATA4 Dominant Permanent/Early 
onset diabetes with 
cardiac defects 













Exome sequencing [38, 95] 















HNF1A Dominant MODY Linkage [19] 




Renal cysts and 
diabetes (RCAD) or 
rare cases with 
transient neonatal 
diabetes  
Candidate gene [98, 99] 




pattern and epilepsy 
Linkage [100] 












diabetes or MODY 







syndrome or MODY 
Candidate gene [14, 103, 104] 





Exome sequencing [42] 
MNX1 Recessive  Permanent neonatal 
diabetes 
Candidate gene [27] 
NEUROD1 Dominant or 
recessive  






Candidate gene [105, 106] 




Candidate gene [107]  
NKX2-2 Recessive Permanent neonatal 
diabetes and corpus 
callosum hypoplasia 
Candidate gene [27] 
PDX1 Dominant or 
recessive 
MODY (dominant) or 
Permanent neonatal 
diabetes (recessive)  
Linkage [22, 108] 






















SLC2A2 Recessive Fanconi-Bickel 
syndrome 
Candidate gene [109]  





Linkage [110]  
SLC29A3 Recessive H syndrome Candidate gene [111] 
STAT3 Dominant Early-onset 
polyautoimmunity 























(dominant de novo) 
Linkage/Exome 
sequencing 




Primrose syndrome Exome sequencing [58] 
ZFP57 Recessive Syndromic transient 
neonatal diabetes 
Linkage [112]  
m.3243A>G 
(Mitochondrial) 
Maternal Diabetes and 
deafness 
Candidate [113]  
 
 
Figure 1: Monogenic diabetes gene in the beta cell. Schematic representation of the monogenic 
diabetes genes (black font) and their subcellular localisation in the beta cell.  
 Figure 1.   
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